How many insider trades does FilingIQ track for INCY?

FilingIQ tracks 1,802 Form 4 insider transactions for INCY (INCYTE CORP), covering filings from Jan 8, 2015 onwards. 30 of those were filed in the last 90 days.

Are INCY insiders net buyers or net sellers?

Across the full Form 4 history for INCY, 71 transactions (4%) were open-market purchases and 335 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does INCY insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is INCY in?

INCYTE CORP (INCY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $20.03B.

INCY insider trading

NasdaqGS Healthcare

INCYTE CORP — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

1,802

Last 90 days

Buys / sells

4% / 19%

Market cap

$20.03B

About INCYTE CORP

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Company website: www.incyte.com

INCY insider activity at a glance

FilingIQ has scored 1,802 insider transactions for INCY since Jan 8, 2015. The most recent filing in our index is dated May 8, 2026.

Across the full history, 71 open-market purchases and 335 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on INCY insider trades is 58.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live INCY trades on FilingIQ Raw filings on SEC EDGAR

Latest INCY Form 4 filings

Iyengar Vijay K EVP, GMAPPS

S Jul 25, 2024

Flannelly Barry P EVP & General Manager US

S Jun 12, 2024

Stein Steven H EVP & Chief Medical Officer

S Aug 1, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading INCY

Stein Steven H

14 trades · score 69.0

13F funds holding INCY

SECTOR GAMMA AS

$33.05M · 7.6% of AUM

Sofinnova Investments, Inc.

$18.62M · 1.0% of AUM

Frequently asked

How many insider trades does FilingIQ track for INCY?: FilingIQ tracks 1,802 Form 4 insider transactions for INCY (INCYTE CORP), covering filings from Jan 8, 2015 onwards. 30 of those were filed in the last 90 days.
Are INCY insiders net buyers or net sellers?: Across the full Form 4 history for INCY, 71 transactions (4%) were open-market purchases and 335 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does INCY insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is INCY in?: INCYTE CORP (INCY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $20.03B.

Methodology & sources

Every INCY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.